Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 5-((1-(6-(trifluoromethyl)-1h-benzo(d)imidazol-2-yl)-1a,6b-dihydro-1h-cyclopropa(b)benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyrdin-2(1h)-one
2. Bgb-283
3. Lifrafenib
1. Lifirafenib
2. Bgb-283
3. 1446090-77-2
4. 1446090-79-4
5. Bgb283
6. Lifirafenib [usan]
7. 5-(((1r,1as,6br)-1-(6-(trifluoromethyl)-1h-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1h-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1h)-one
8. Bgb 283
9. 8762xzs5zf
10. 5-(((1r,1as,6br)-1-(6-(trifluoromethyl)-1h-benzimidazol-2-yl)-1a,6b-dihydro-1h-cyclopropa(b)benzofuran-5-yl)oxy)-3,4-dihydro-1h-1,8-naphthyridin-2-one
11. 5-[[(1r,1as,6br)-1-[6-(trifluoromethyl)-1h-benzimidazol-2-yl]-1a,6b-dihydro-1h-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one
12. 1,8-naphthyridin-2(1h)-one, 5-(((1r,1as,6br)-1a,6b-dihydro-1-(6-(trifluoromethyl)-1h-benzimidazol-2-yl)-1h-cyclopropa(b)benzofuran-5-yl)oxy)-3,4-dihydro-
13. 5-({(1r,1as,6br)-1-[5-(trifluoromethyl)-1h-benzimidazol-2-yl]-1a,6b-dihydro-1h-cyclopropa[b][1]benzofuran-5-yl}oxy)-3,4-dihydro-1,8-naphthyridin-2(1h)-one
14. Compound 2.2b
15. 5-{{(1r,1as,6br)-1-[5-(trifluoromethyl)-1h-benzimidazol-2-yl]-1a,6b-dihydro-1h-cyclopropa[b][1]benzofuran-5-yl}oxy}-3,4-dihydro-1,8-naphthyridin-2(1h)-one
16. Lifirafenib [inn]
17. Lifirafenib (usan/inn)
18. Unii-8762xzs5zf
19. Bgb-283;beigene-283
20. Lifirafenib [who-dd]
21. Gtpl8958
22. Chembl4209157
23. Schembl15085288
24. Bdbm372968
25. Ex-a1473
26. Us9895376, Compound 2.2b
27. Whc09077
28. Whc09079
29. Lifirafenib;bgb-283;beigene-283
30. Bdbm50453816
31. Who 10554
32. Zinc68764621
33. Cs-6308
34. Db14773
35. Ac-35880
36. Ac-36373
37. Hy-18957
38. D11410
39. A900647
40. Q27075193
41. 3k3
| Molecular Weight | 478.4 g/mol |
|---|---|
| Molecular Formula | C25H17F3N4O3 |
| XLogP3 | 3.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 3 |
| Exact Mass | 478.12527490 g/mol |
| Monoisotopic Mass | 478.12527490 g/mol |
| Topological Polar Surface Area | 89.1 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 845 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
27
PharmaCompass offers a list of Lifirafenib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lifirafenib manufacturer or Lifirafenib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lifirafenib manufacturer or Lifirafenib supplier.
PharmaCompass also assists you with knowing the Lifirafenib API Price utilized in the formulation of products. Lifirafenib API Price is not always fixed or binding as the Lifirafenib Price is obtained through a variety of data sources. The Lifirafenib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Beigene-283 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Beigene-283, including repackagers and relabelers. The FDA regulates Beigene-283 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Beigene-283 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Beigene-283 supplier is an individual or a company that provides Beigene-283 active pharmaceutical ingredient (API) or Beigene-283 finished formulations upon request. The Beigene-283 suppliers may include Beigene-283 API manufacturers, exporters, distributors and traders.
Beigene-283 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Beigene-283 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Beigene-283 GMP manufacturer or Beigene-283 GMP API supplier for your needs.
A Beigene-283 CoA (Certificate of Analysis) is a formal document that attests to Beigene-283's compliance with Beigene-283 specifications and serves as a tool for batch-level quality control.
Beigene-283 CoA mostly includes findings from lab analyses of a specific batch. For each Beigene-283 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Beigene-283 may be tested according to a variety of international standards, such as European Pharmacopoeia (Beigene-283 EP), Beigene-283 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Beigene-283 USP).